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Abbreviated Title 
Recellularization of Cartilage via Elastin Fibre Channels 
 
Abstract 
Decellularized tissue matrices are promising substrates for tissue generation by stem 
cells to replace poorly regenerating tissues such as cartilage. However, the dense 
matrix of decellularized cartilage impedes colonisation by stem cells. Here, we show 
that digestion of elastin fibre bundles traversing auricular cartilage creates channels 
through which cells can migrate into the matrix. Human chondrocytes and bone 
marrow-derived mesenchymal stromal cells efficiently colonize elastin-treated 
scaffolds through these channels, restoring a glycosaminoglycan-rich matrix and 
improving mechanical properties while maintaining size and shape of the restored 
tissue. The scaffolds are also rapidly colonized by endogenous cartilage-forming cells 
in a subcutaneously implanted osteochondral biopsy model. Creating channels for 
cells in tissue matrices may be a broadly applicable strategy for recellularization and 
restoration of tissue function. 
 
1. Introduction 
Cartilage consists of a single cell type, the chondrocyte, embedded in a flexible yet 
sturdy matrix [1,2]. It lacks blood vessels, nerves, as well as lymphatics, and in adults 
heals poorly after injury [1]. The combination of perceived structural simplicity and 
substantial clinical demand has made a prime tissue-engineering target for scientists. 
However, the mechanical characteristics of cartilage result from a complex matrix 
architecture that has been challenging to replicate [2–4].   
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One experimental approach to engineering tissue with the mechanical characteristics 
of cartilage has been to introduce chondrogenic cells into decellularized allogeneic or 
xenogeneic cartilage. Not only would this yield a scaffold with low immunogenicity, but 
the native cartilage environment may promote chondrogenesis in the newly introduced 
cells and thus facilitate restoration of the mechanical properties [reviewed in [5]]. 
Multiple protocols to remove cells from cartilage, using enzymes, detergents, 
denaturing chemicals, physical forces and combinations thereof have been developed 
[6–12]. However, the dense cartilage matrix has impeded the migration of cells into 
decellularized cartilage [reviewed in [13]].  
Here we explore whether specific structural features of auricular cartilage would allow 
the introduction of cells into the matrix. Hyaline cartilage as found in the trachea, ribs, 
nasal septum and joints consists of a dense uninterrupted collagen type II matrix. 
Elastic cartilage, as found in the epiglottis, outer ear and eustachian tubes, contains a 
collagen type II matrix but is additionally traversed by elastin fibre bundles [1]. Due to 
the high prevalence of joint defects and the severity of tracheal injury, most research 
has focussed on the decellularization of hyaline cartilage. In this work, we aim to show 
that removal of the elastic fibre bundles traversing elastic cartilage generates channels 
through which cells can access the inner matrix and secrete glycosaminoglycans in 
situ, generating a cartilage-like tissue.  
 
2. Materials and Methods  
2.1 Decellularization with Elastase 
Auricular cartilage was harvested from the ears of a human donor post-mortem [age 
64] (body donation to Erasmus MC) or bovine calves [age: < eight months] (T. Boer & 
Zn. Nieuwerkerk aan den IJssel, the Netherlands). After washing the ears with water, 
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skin and muscle tissue were removed with a scalpel. Biopsies were taken using ∅6 or 
∅8 mm biopsies punches (Stiefel Laboratories Nederland, Zeist, the Netherlands) and, 
where indicated, the perichondrium was removed using a scalpel. Subsequently, the 
cartilage was washed three times with deionized water (ISO 3696 Grade I), three times 
freeze-thawed in deionized water [-80°C to 37°C] and subsequently sterilized by 
incubation in 5% H2O2 (Sigma-Aldrich, Zwijndrecht, the Netherlands) at 37°C for at 
least one hour. The cartilage was then rinsed three times with sterile deionized water 
for five minutes and incubated for 24 hours rotating at 37°C in elastase solution: 3 
units [Type IV] (Sigma-Aldrich) or 10 units (Gold Biotechnology Inc., St. Louis, USA) 
porcine pancreatic elastase per ml of 0.2 M tris(hydroxymethyl)-aminomethane [TRIS] 
HCl (Sigma-Aldrich) in water, set to a pH of 8.6. After elastase treatment, scaffolds 
were washed three times in sterile deionized water for five minutes. To hasten removal 
of cell debris, cartilage was exposed to physical strain: a snap freeze-thaw cycle [-
190°C to 37°C], two eight-minute sonication rounds at 42 kHz [70-Watt water bath 
sonicator] and vortexing three times, in absence of liquid, for about 30 seconds at 
2,500 RPM. Scaffolds were stored in sterile deionized water at -20°C until further 
processing. Matristypt™ collagen meshes (Dr Sulawek Skin & Healthcare AG, 
Billerbeck, Germany) were used as control scaffolds for cell seeding. 
To test sterility of the decellularized cartilage, samples were incubated in MEM-α 
[Gibco brand] (Thermo-Fisher, Waltham, US) containing 10% heat-inactivated foetal 
calf serum [FCS] (Lonza, Basel, Switzerland) for 24 hours at 37°C, rotating at 30 RPM. 
Afterwards presence of bacteria and fungi was evaluated by light microscopy and 
unsterile samples were discarded. 
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2.2 Cell Sourcing and Culture 
2.2.1 Bone Marrow-derived Multipotent Stem Cells  
Human bone marrow-derived multipotent stem cells [BMSCs] were isolated from 
femoral marrow aspirates of adults undergoing total hip replacement (MEC-2004-142 
& MEC-2015-644; age: 49-71; informed consent provided) or left-over iliac crest bone 
chips of children undergoing palate cleft reconstruction (MEC-2014-16; age: 9-13; 
implicit consent). Bone chips were swirled twice in 10 ml expansion medium and the 
medium than plated in 175cm2 culture flasks, whereas bone marrow aspirates were 
diluted with expansion medium to 20 ml and plated in 175 cm2 culture flasks. BMSCs 
expansion medium consisted of: MEM-α (Thermo-Fisher), containing 10% heat-
inactivated FCS [Gibco brand] (Thermo-Fisher), 50 μg/mL gentamicin [Invitrogen Life 
Technologies brand] (Thermo-Fisher), 1.5 μg/ml amphotericin B [Fungizone™] 
(Thermo-Fisher), 0.1 mM L-ascorbic acid 2-phosphate and 1 ng/mL basic Fibroblast 
Growth Factor 2 [FGF2] (R&D Systems, Minneapolis, USA). After 24 hours, the flasks 
were gently washed with PBS containing 1% FCS and adherent cells expanded in 
expansion medium (refreshed every three days) till ca. 80% confluence. Afterwards 
cells were passaged to 2,300 cells/cm2 into expansion medium with 250 ng/ml WNT3A, 
made in house by genetically modified Schneider Drosophila melanogaster S2 cells 
and purified as previously described [14]. Medium was refreshed daily and cells 
passaged once cells reached ca. 80% confluence. BMSCs were used for 
recellularization at passages two to four.  
 
2.2.2 Articular Chondrocytes Sourcing and Culture 
Human articular chondrocytes (ACs) were isolated from knee joints of patients 
undergoing total knee replacement (MEC-2011-371 [surgical waste material], age: 58-
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68). Small chips were cut from macroscopically healthy areas of the cartilage using a 
scalpel and rinsed twice in PBS. The chips were then digested for 1 hour with 2 mg/ml 
protease (Sigma-Aldrich) in PBS followed by 0.5 mg/ml collagenase B (Roche 
Diagnostics, Rotkreuz, Switzerland) in DMEM (Lonza) with 10% heat-inactivated FCS 
(Thermo-Fisher) gentamicin [50 µg/mL] (Thermo-Fisher), and 1.5 µg/mL amphotericin 
B [Fungizone™] (Thermo-Fisher), rotating for at least twelve hours at 37°C.  
Afterwards, the solution was filtered through a 100 µm strainer (BD Biosciences, 
Franklin Lakes, USA), centrifuged, and the pellet washed twice in PBS. Chondrocytes 
were then plated at 7,500 cells/cm2, expanded in the above mentioned DMEM-based 
medium (refreshed twice a week) and passaged when 80% confluence was reached. 
Chondrocytes were used for recellularization after one or two passages.  
 
2.3 Cell Seeding  
2.3.1 Onto the Scaffold Surface  
Scaffolds without perichondrium were placed in the lids of 2 ml polypropylene 
microcentrifuge tubes (Thermo-Fisher) to ensure that seeded cells would settle on the 
scaffold only. Per mm3 of sample, ca. 8,500 BMSCs or ACs were seeded statically, 
unless otherwise indicated, in the appropriate expansion medium (see above) and 
incubated in the inverted tubes for 24 hours at 37°C. When bilateral seeding was 
desired, scaffolds were turned after ca. twelve hours. Afterwards samples were 
transferred into 1/2 cm2 wells of 48/24-well cell culture plates. To compare static and 
rotating seeding, scaffolds were placed into 2 ml polypropylene microcentrifuge tubes 
filled with cell suspensions of the indicated cell concentrations and incubated at 37°C 
either statically or rotating at a 45° angle. 
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2.3.2 Injection into the Scaffolds  
For scaffolds with perichondrium, the ∅8 mm scaffolds were held tightly with tweezers 
and a concentrated cell suspension of less than 100 µl injected using a 27-gauge 
needle at three points (total ca. 8,500 cells/mm3 scaffold volume). The scaffolds were 
then washed twice in PBS to remove cells on the surface and transferred to 2-4 cm2 
wells of 24/12-well cell culture plates.  
 
2.4 Pellet-based Chondrogenicity Assay and Chondrogenic Differentiation  
To evaluate chondrogenic differentiation potential, at least three pellets from each 
donor were formed by centrifuging 200,000 BMSCs or ACs in conical non-adherent 
polypropylene 15 ml tubes (Thermo-Fisher) at 300 g for eight minutes. Pellets were 
then cultured in 0.5 ml/tube chondrogenic differentiation medium; recellularized 
cartilage in 0.5 to 2 ml depending on volume.  Chondrogenic differentiation medium 
contained: high glucose DMEM [Gibco GlutaMAX+] (Thermo-Fisher), 1:100 ITS+ plus 
mix [insulin, transferrin and selenous acid] (BD Biosciences), 40 μg/ml L-proline 
(Sigma-Aldrich), 1 mM sodium pyruvate (Thermo-Fisher), 10 ng/ml TGF-β1 (R&D 
Systems), 1.5 µg/mL amphotericin B [Fungizone™] (Thermo-Fisher) and 50 μg/ml 
gentamicin (Thermo-Fisher). For BMSC chondrogenic differentiation 100 nM 
dexamethasone (Sigma-Aldrich) was added [15]. Medium was refreshed twice a week 
for 35 days, after which the samples were harvested, rinsed in PBS and fixed in 4% 
formalin for 24 hours. 
 
2.5 Migration Assays 
2.5.1Migration in Response to a Serum Gradient 
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To serve as a serum reservoir, two ∅8 mm Matristypt™ collagen meshes (Dr Sulawek 
Skin & Healthcare AG) were placed at the bottom of 0.33 cm2 wells (96 well plate). 
Then 15 µl FCS (Lonza) or 15 µl BMSC expansion medium were added to the meshes 
and allowed to soak in. Onto the collagen meshes, 1 mm thick, ∅8 mm elastase-
treated auricular cartilage scaffolds were stacked and the 150 µl expansion medium 
without or with 10% FCS respectively added. Subsequently, ca. 2,500 cells/mm2 were 
added into the well and allowed to settle onto the scaffolds. Since the diameter of the 
scaffolds was ca. 1 mm larger than that of the well, the scaffolds sealed the collagen 
meshes off, limiting cell migration to the cartilage. Scaffolds were then incubated for 
six days before harvest and processed as paraffin block sections, described below.  
 
2.5.2 Migration in Serum-containing versus TGFβ1-containing Media 
BMSCs were unilaterally seeded at 2,500 cells/mm2 onto ca. 1 mm deep, ∅8 mm 
elastase-treated auricular cartilage scaffolds without perichondrium. The seeded 
scaffolds were cultured in either the serum-free, TGFβ1-containing medium we used 
for chondrogenic differentiation of BMSCs (chondrogenic medium, see above) with the 
serum-containing or the TGFβ1-free medium used for BMSC expansion (expansion 
medium). The scaffolds were incubated statically at 37°C and the appropriate medium 
refreshed daily. To visualize viable cells, on the day of harvest (one day or three days 
after seeding) Calcein AM (Thermo-Fisher) was added into the medium to 0.5 µM and 
the samples incubated for 30 minutes at 37°C in the dark. Subsequently, scaffolds 
were washed in PBS, harvested and then processed as cryosections as described 
below.  
 
2.6 Articular Joint Defect Model 
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To evaluate articular cartilage defect closure we used a bovine osteochondral biopsy 
model system, developed previously by our lab [16,17]. In brief, we employed a hollow 
drill (DePuy Synthes, Palm Beach Gardens, USA) to create ∅8 mm osteochondral 
biopsies of four proximal sesamoid bones from fresh metacarpophalangeal joints from 
calves [age <8 months] (T. Boer & Zn.). The biopsies were rinsed twice with saline, 
then cut to about 5 mm in length and incubated overnight in full expansion medium.  
Using a ∅6 mm dermal biopsy punch (Stiefel Laboratories) and a scalpel, chondral or 
osteochondral defects were created. The defects were then washed twice in saline 
and ∅6 mm elastase-treated auricular cartilage scaffolds of ca. 0.7-1 mm [chondral] 
or 1.2-1.5 mm [osteochondral] height placed into the defects. The cartilage side of 
each biopsy was covered with an ∅8 mm Neuro-Patch™ membrane (B. Braun AG, 
Melsungen, Germany) to prevent murine tissue ingrowth. The samples were incubated 
for less than two hours in expansion medium until subcutaneous implantation into 
female NMRI nu/nu mice [ethical approval: DEC EMC3284] (Taconic Biomedical, 
Rensselaer, USA). Handling and housing of the mice was carried out in accordance 
with the EU Directive 2010/63/EU for animal experiments, with at least two mice 
housed together in one cage. Per mouse, four randomized chondral or osteochondral 
biopsies were implanted under isoflurane anaesthesia. In total n=12 elastase-treated 
auricular cartilage scaffolds were transplanted into n=4 chondral and n=8 
osteochondral biopsies, distributed over two experiments with n=4 and n=6 mice 
respectively. Mice received 0.05 mg/kg bodyweight of Temgesic (Reckitt Benckiser, 
Slough, UK) one hour before and six to ten hours after surgery and 25 mg/kg 
bodyweight of amoxicilline (Dopharma Nederland, Raamsdonksveer, the Netherlands) 
during surgery. After two, four or ten weeks as indicated mice were euthanized by 
cervical dislocation. Cylinders were carefully explanted, surrounding tissue inspected 
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for macroscopic signs of inflammation and damage, fixed in 4% formalin for five days, 
subsequently decalcified using 10% formic acid (Sigma-Aldrich) for two weeks and 
embedded in paraffin.  
 
2.7 Histological and Immunohistochemical Stainings 
Paraffin embedded samples were sectioned at 6 μm thickness, placed on glass slides, 
dried and rehydrated. Frozen samples were sectioned at 10 μm thickness, frozen for 
at least 24 hours, then slowly thawed, air-dried and fixed using 100% acetone (Sigma-
Aldrich). Both cryosections and paraffin block sections were stained with Haematoxylin 
(Sigma-Aldrich) and 2% Eosin (Merck Group, Darmstadt, Germany), 0.04% Thionin 
solution (Sigma-Aldrich) or Resorcin-Fuchsin solution [Klinipath brand] (VWR 
International, Breda, the Netherlands) according to manufacturer’s instruction. 
Sections were subsequently dehydrated by increasing concentrations of ethanol 
(Sigma-Aldrich) and Xylene (Sigma-Aldrich) and sealed under a glass coverslip with 
PERTEX™ (HistoLab Products, Askim, Sweden). 
For elastin staining, sections were incubated in 0.25% trypsin dissolved in PBS for 20 
minutes at 37°C. Subsequently, non-specific binding sites were blocked with 10% goat 
serum in PBS and sections were stained for one hour with a monoclonal anti-elastin 
antibody [BA-4] (Sigma) diluted to 10 ug/ml in PBS. Sections were then incubated for 
30 minutes at room temperature with an anti-mouse biotin labelled antibody diluted 
1:50 in PBS with 5% FCS. Afterwards, sections were incubated for 30 minutes at room 
temperature with HRP–streptavidin conjugate (Biogenex, California, USA) diluted 1:50 
in PBS/1% BSA. Labelling was detected using enzymatic turnover of a Neu Fuchsin 
substrate (Chroma, Köngen, Germany). Sections were then airdried overnight and 
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sealed under a glass coverslip with Vectamount [#H5000] (Vector Laboratories, 
Burlingame, USA). 
 
2.8 Imaging, Cell Migration and Cell Density Quantification 
Stained sections were imaged using cellSens™ Standard software (Olympus Europe, 
Hamburg, Germany) with a 5-megapixel digital 14-bit colour camera [model UC50] 
(Olympus Europe) attached to an upright light microscope for slides [model BX 40] 
(Olympus Europe). Cell migration distance was measured by creating bins of 250 µm 
height and 2,250 µm width (0.5 mm2) with the linear measurement tool in cellSens™ 
and cell numbers were counted manually in ImageJ (NIH, Bethesda, USA) [18]. The 
first 25 µm from the cartilage surface were excluded to discount cells adherent but not 
migrating.  Cell density was determined by counting cells per 0.1 mm2 field, with six 
(seeding) or twelve (injection) fields per sample and depth. Cell distance distribution 
was determined by measuring n=60 nuclei-nuclei distances per donor on H&E, 
excluding cells sharing lacunae or within 25 µm of the scaffold surface. The maximum 
width of cell distributions for an injection side was determined by measuring the 
distance between the cells furthest apart either perpendicular or parallel to the 
perichondrium in six different areas per sample.  All quantification of cell numbers was 
performed blinded by one person (J.L.), with the exception of supplementary figure 
2(b), which was scored unblinded.  
 
2.9 Mechanical Testing of Native, Elastase-treated and Recellularized Cartilage 
Nanoindentation of bovine auricular cartilage scaffolds was performed using a 
displacement-controlled nanoindenter [model name Piuma] (Optics11, Amsterdam, 
the Netherlands) with a spherical probe [stiffness: 58.3 N/m; radius: 51 µm] using a 
measurement protocol based on Moshtagh [19]. Force-displacement curves were 
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generated based on cantilever deflection and indentation depth as controlled by a 
piezoelectric motor. For indentation, each cartilage biopsy was submerged in PBS 
within a glass petridish, held in place by an agarose mould. The probe was calibrated 
and then for each scaffold a square matrix of 16 indentation points [250 µm apart] 
were measured. For each indentation, the probe was held above the surface for 0.5 
seconds, followed by indentation to 15 µm for 1 second, holding the probe at 15 µm 
seven seconds, unloading over 20 seconds and then pausing for 0.5 seconds prior to 
moving to the next indentation point. The Piuma software (Optics11) then calculated 
the effective elastic modulus based on the slope of the stress-strain curve using the 
Oliver-Pharr theory[19] Minimal variability between different measurement sessions 
was ensured by indenting a set [n=3] of control scaffolds (decellularized, untreated) 
during every session.  Since removal of elastin with elastase can dramatically alter the 
viscoelastic behaviour of auricular cartilage [20], we refer to the measured values as 
stress-strain modulus. In total 8x untreated, 10x decellularized and 44x recellularized 
(>3 per donor) cartilage scaffolds were indented.   
 
2.10 Statistics 
Analysis of numerical data was performed in SPSS 20 (IBM, North Castle, USA). 
Migration in expansion and chondrogenic medium were compared pairwise for day 
three using the Mann-Whitney-U test. Migration into different depths in presence and 
absence of serum were tested, paired by depth, using the Wilcoxon signed-rank test. 
The stress-strain modulus values were compared pairwise for all samples using the 
Kruskal-Wallis Test (indicated significance is for the pairwise comparison of all 
scaffolds to decellularized-only scaffolds). We set p=0.05 as cut-off for significant 
13 
 
differences for all tests, with the p-values given in the figure legends (rounded up if 
p<0.01).  
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3. Results 
3.1 Recellularization of auricular cartilage after removal of elastin fibres 
To determine if removal of elastin permits recellularization of cartilage, we digested 
elastin in devitalized bovine auricular cartilage scaffolds by treatment with 3 U/ml 
pancreatic elastase for 24 hours. Staining with resorcin-fuchsin showed that the 
treatment removed elastin fibres, opening the otherwise dense pericellular matrix 
containing the chondrocytes (lacunae) and leaving behind channels traversing the 
collagen network (figure 1(a)). The elastase treatment was also sufficient to remove 
most cell remnants and deplete glycosaminoglycans (figure 1(b)). Elastin depletion 
was elastase dose-dependent, with 3 to 10 U/ml (brand-dependent) elastase 
completely depleting elastin fibres as detected by resorcin-fuchsin staining in bovine 
auricular cartilage (supplementary figure 1(a), (b)). To confirm depletion of elastin seen 
on resorcin-fuchsin staining, we performed immunohistochemistry with a monoclonal 
elastin-specific antibody ((supplementary figure 1(c)). Moreover, loss of 
glycosaminoglycans, as indicated by thionin staining, as well as cell remnants, visible 
on thionin and H&E stainings, were associated with elastin depletion (supplementary 
figure 1(a), (b)). Elastase treatment was equally efficient in clearing elastin in human 
and bovine auricular cartilage, but glycosaminoglycan depletion required higher 
elastase concentrations in human compared to bovine cartilage (supplementary figure 
1(d), (e)). Overall, elastase treatment renders bovine and human auricular cartilage 
porous, decellularizes it and depletes glycosaminoglycans.  
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Figure 1. Elastase treatment removes elastin fibres and glycosaminoglycans, permitting 
recellularization. (a, b) Bovine auricular cartilage before and after treatment with elastase, stained 
with (a) resorcin-fuchsin (highlights elastic fibres) or (b) thionin (marking glycosaminoglycans). Scale 
bars = 200 µm. White arrowheads indicate lacunae where cells are/were located in, black arrowheads 
elastin fibre bundles/channels. (c) Bovine auricular cartilage treated with elastase stained with 
haematoxylin and eosin (H&E) six days after being unilaterally seeded with BMSCs. Cells tunnelling 
through the channels left behind after elastin fibre removal are highlighted in the insets. Scale bars = 
100 µm; horizontal dotted white lines in (c) ca. 200 µm, 400 µm and 600 µm from seeded surface. 
(d) H&E staining of two bovine auricular cartilage scaffolds not exposed to elastase but undergoing 
all other steps of the decellularization protocol and then cultured for six days after seeding with 
BMSCs. Magnified panels show nuclei of resident chondrocytes (white arrowheads) remaining in the 
matrix and seeded BMSCs (black arrowheads) not invading. Scale bars = 200 µm. (e) H&E staining 
of a bovine auricular cartilage scaffold treated with 0.1 U/ml elastase to partially remove elastin and 
then cultured for six days after seeding with BMSCs. Black arrowheads indicate cells that have 
entered the matrix furthest. Scale bar = 200 µm (f)H&E staining showing cells adherent to elastase-
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treated bovine articular and nasal cartilage scaffolds cultured for six days after seeding with BMSCs. 
Black arrowheads highlight cells incapable of invading the articular and nasal cartilage matrix. 
Highlighted by a white arrowhead are cells that invaded the lacunae cut open during processing but 
did not migrate further into the scaffold. Scale bars = 200 µm. . (g, h) Depletion of glycosaminoglycans 
and lack of elastin fibres visible on (g) rescorcin-fuchsin and (h) thionin stained elastase treated 
bovine articular and nasal cartilage scaffolds. Scale bars = 200 um. 
 
To determine if the channels created by elastase treatment allowed cell migration, we 
seeded the elastase-treated auricular cartilage scaffolds with 8,500 human bone 
marrow-derived multipotent stem cells [BMSCs] (expanded for two to three passages 
with WNT3A and FGF2) per mm3 scaffold. BMSCs are attractive for articular cartilage 
repair, since they are highly chondrogenic they can be expanded, and the donor site 
morbidity caused by bone marrow aspiration is limited [21]. We have previously shown 
that culturing with WNT3A and FGF2 maintains BMSC’s chondrogenic capacity during 
expansion [22]. The ca. 1 mm thick scaffolds were seeded unilaterally for 24 hours, 
leading to the deposition of cell layers on the scaffold surface. We sectioned scaffolds 
six days after seeding with BMSCs to investigate the extent of cell invasion (figure 
1(c)). We found that cells invaded the scaffolds with 53 ± 15% of invading cells having 
migrated up to 200 µm from the surface, 25 ± 4% 200 to 400 µm, 14 ± 9% 400 to 600 
µm and 7 ± 8% 600 to 800 µm. Cells that invaded were frequently found stretched 
within the channels, radiating from the seeding surface, indicating migration along the 
voids created by elastin fibre removal (figure 1(c)). On the other hand, bovine auricular 
cartilage not treated with elastase and therefore lacking channels, was not invaded by 
cells (figure 1(d)). Moreover, when exposure to elastase was limited and therefore 
elastin only removed from part of the biopsy, cell invasion was limited to areas where 
elastin fibres were cleared (figure 1(e)). This suggests that removal of elastin by 
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elastase treatment is responsible for rendering auricular cartilage permeable to cells. 
To further confirm that elastase allowed recellularization by removing elastin fibre 
bundles, we treated bovine nasal and articular cartilage, which are hyaline and lack 
elastin fibre bundles, with elastase. While this depleted glycosaminoglycans from both 
nasal and articular cartilage, no visible channels formed, and cells did not invade into 
the matrix (figure 1(f)-(h)). In summary, this indicates removal of elastin fibre bundles 
allows cells to invade auricular cartilage.   
 
3.2 Static Seeding and Chondrogenic Differentiation Conditions Facilitate Uniform 
Recellularization of Elastase-treated Auricular Cartilage  
We observed that the number of cells invading the scaffold correlated with the number 
of cells on the closest scaffold surface. We therefore compared static and rotating 
seeding at different cell concentrations to identify under which condition cells adhered 
densely and uniformly to the scaffold surface. Rotating the scaffolds continuously or 
intermittently during seeding induced cell clumping as well as irregular seeding and 
was not further explored. Maintaining a consistent total seeded cell number, we found 
that a 500 cells/µl suspension yielded a good combination of cell density and uniformity, 
with other concentrations yielding significantly lower cell densities or showing large 
sample variation (supplementary figure 2(a), (b)). Exposing the scaffold to the cell 
suspension for longer than 24 hours did not yield higher cell densities [data not shown]. 
BMSCs remained viable and attached to the scaffold throughout a culture period of at 
least 30 days (supplementary figure 2(c)). Culture-expanded chondrocytes also allow 
generation of autologous cartilage, and might be favourable for small defects or when 
donor site morbidity is not of concern (e.g. in microtia, where cells can be derived from 
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the to-be-reconstructed malformed auricle) [23–25]. Expanded, dedifferentiated adult 
human articular chondrocytes (ACs) adhered well to elastase-treated auricular 
cartilage and remained viable for at least 30 days (supplementary figure 2(d), offering 
an alternative to BMSCs.  Given that 24-hour seeding with 500 cells/µl yielded a high 
average cell density with low variation, we continued with this set-up for all subsequent 
experiments. 
We observe that cell density within the scaffold declined with distance to the seeding 
surface (figure 1(c)). BMSCs and chondrocytes migrate towards attractants contained 
in foetal calf serum [26,27]. We therefore tested whether a serum gradient encouraged 
BMSCs migration by placing a serum-laden sponge against the scaffolds, opposite to 
the cell seeding surface. The serum gradient significantly increased the number of 
BMSCs migrating into the tissue (figure 2(a)). Notwithstanding, distribution of cells 
within the scaffolds remained skewed towards areas within 500 µm of the seeding 
surface.  
In vivo, transforming growth factor 1 beta (TGFβ1) stimulates migration of BMSCs 
through tissues [28,29]. TGFβ1 also induces chondrogenic differentiation in BMSCs 
and de-differentiated chondrocytes [15,30,31], which is required to restore the 
decellularized matrix.  Because chondrogenic medium may thus enhance both 
migration of seeded cells and matrix regeneration, we compared migration in a serum-
free, TGFβ1-containing medium commonly used for chondrogenic differentiation of 
BMSCs [15] (chondrogenic medium) with the serum-containing, TGFβ1-free medium 
we used for BMSC expansion (expansion medium). Three days after seeding, 
significantly more BMSCs (2.9 ± 0.7-fold increase) migrated into the scaffolds in 
chondrogenic compared to expansion medium (figure 2(b), (c)).  
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Since BMSCs migrated through the scaffold in chondrogenic medium, we assessed 
if in a timeframe sufficient for chondrogenic differentiation and matrix synthesis in 
vitro (35 days) [22], BMSCs would recellularize the scaffolds to cell densities 
comparable to native cartilage. Scaffolds (height 1mm, ∅8 mm, ca. 50 mm3) were 
seeded with 450,000 BMSCs and cell density quantified on H&E stained 6 µm 
sections after 35 days culture in chondrogenic medium. Cell density averaged 150 
cells/mm2 and varied little between BMSC donors (figure 2(d)). The average cell 
density of recellularized scaffolds was lower than that of native bovine (239 ± 53 
cells/mm2) or human (306 ± 67 cells/mm2) auricular cartilage as well as that of 
human septal nasal cartilage (226 cells/mm2) [32], but higher than that of human 
femoral condylar articular (layer dependently 32-76 cells/mm2) [33] or costal 
cartilage (27 cells/mm2) [33] (figure 2(d)). Cell density was slightly higher near the 
seeding surface, with the innermost areas containing on average 23% less cells than 
areas below the surface. Average cell-cell distance in the recellularized scaffolds 
was 63 ± 28 µm, slightly higher than the 57 ± 21 µm in native bovine auricular 
cartilage (supplementary figure 3(a)). These findings indicate that BMSCs 
recellularize the elastase-treated auricular cartilage scaffolds to levels comparable 
to native cell density and distribution. 
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Fig. 2 In chondrogenic differentiation conditions cells rapidly distribute through the matrix to near 
native densities. (a) Plot showing the number of BMSCs that have migrated into zones at different 
depths from the seeding surface after six days culture in DMEM with 10% serum on both sides of the 
scaffold (no gradient) or DMEM with no serum and an 10%-equivalent volume serum on the side 
opposite of the cells (gradient). For each of n=3 samples per depth the counts of four 100µm-apart 
sections were averaged. Error bars = SD. * p <0.01 (Wilcoxon signed-rank test, paired by depth). (b) 
Plot showing the number of BMSCs that have migrated into the scaffold (>25 μm from scaffold 
surface) after one- or three-days of culture in chondrogenic or expansion medium. n=4 scaffolds, 
error bars = SD, Mann-Whitney-U test, 2-tailed significance * p=0.03. (c) Representative micrographs 
of day three samples from (b) stained with CalceinAM to mark live cells and merged with brightfield 
images to show matrix boundaries or stained with H&E. Scale bars = 100 µm. (d) Cells per mm2 
plotted for native bovine and human auricular cartilage as well as elastase-treated bovine auricular 
cartilage scaffolds superficially seeded with BMSCs and cultured 35 days culture in chondrogenic 
medium. For each of the three donors six non-overlapping fields of 0.1 mm2 were counted for the 
core (inner 250 um) or in the outer areas (>25 μm from surface) of the scaffold. Error bars = SD.  
Blue bars indicate cell densities from literature for human nasal [32], articular (range of all depths) 
[33] as well as costal cartilage [33]. 
 
3.3 Overcoming the Perichondral Barrier by Cell Injection  
Plastic surgery of the auricle (outer ear), the nasal septum or alar nasi is one area 
where auricular cartilage matrix scaffolds could be employed. Since these cartilage 
structures are lined by perichondrium which contributes to integration with the 
21 
 
surrounding tissues as well as to mechanical properties of the structure, we studied 
grafts with perichondrium intact.  However, in the cellular (cambium) layer  of the 
perichondrium surrounding the auricular cartilage that lacks elastin fibres (figure 3(a)), 
no channels formed after elastase treatment (figure 3(b)). Furthermore, no cells could 
be detected in the cambium layer or the underlying cartilage after recellularization 
(figure 3(c)). However, when the perichondrium was removed from one side prior to 
recellularization, cells were observed below the cambium layer on the other side 
(figure 3(d)), showing that the seeded cells were able to migrate to the cambium layer 
but could not cross the perichondrium. To find a method to recellularize full thickness 
cartilage, we assessed whether BMSCs would distribute throughout the matrix upon 
injection into scaffolds without removal of the perichondrium. Histology indicated that 
the matrix was minimally distorted after injection, with visible damage far smaller than 
the needle diameter (figure 3(e)). As with superficial seeding, we compared cell 
migration in chondrogenic with expansion medium. Six days after injection, BMSCs 
were found throughout the matrix surrounding the injection sites and average cell 
density at the centre of the scaffold was 193 ± 88 cells/mm2 for culture in chondrogenic 
and 197 ± 80 cells/mm2 for expansion medium (figure 3(f)). 800 µm from the centre of 
the scaffold, average cell density was 214 ± 124 cells/mm2 for culture in chondrogenic 
and 168 ± 60 cells/mm2 for expansion medium. There were no significant differences 
between either the media nor between central and peripheral areas within the scaffold 
(figure 3(f)). Overall cell density in scaffolds cultured in chondrogenic medium (193 ± 
88 cells/mm2) was not significantly different (p = 0.24, Mann-Whitney-U test) from that 
of native bovine auricular cartilage (239 ± 53 cells/mm2), but significantly lower (p 
<0.01) than native human auricular cartilage human (306 ± 67 cells/mm2). Moreover, 
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cell density after injection for both media was higher than that of human costal and 
articular cartilage, but lower than that of human nasal septal cartilage (figure 3(f)).  
To estimate what scaffold area would be recellularized per injection, we measured cell 
spread from visible injection sites on histology. Cells spread approximately 2 mm 
parallel to the perichondrium, with little difference between media (supplementary 
figure 3(b)). Perpendicular to the perichondrium cells spread 849 ± 174 µm in 
chondrogenic medium (covering 86% of the entire inter-perichondral distance of 997 
± 251 µm of those samples) and 871 ± 49 µm(representing 91% of the entire inter-
perichondral distance of 953 ± 55 µm of those samples) in expansion medium 
(supplementary figure 3(c)). Together, these data indicate that injection of cells allows 
uniform recellularization of elastase-treated auricular cartilage scaffolds with intact 
perichondrium on both sides.  
 
Figure 3 Prevention of  cell invasion by perichondrium can be overcome by injecting cells. 
(a) Fibrous (FP) and cambium layer (CP) of the perichondrium in a section of untreated bovine 
auricular cartilage stained for elastin. Dotted lines indicate borders between FP and CP (black) and 
CP and cartilage (white). (b) H&E staining of a full thickness elastase-treated bovine auricle with 
many channels present in the centre (black arrowheads) but not in the FP or CP. (c) H&E staining 
of elastase-treated auricular cartilage recellularized from the perichondrium side. Cells (black 
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arrowheads) adhere to and migrate into the FP, but do not cross into the underlying CP or cartilage. 
(d) H&E staining of elastase-treated auricular cartilage with perichondrium removed from one side 
(bottom) but left intact on the other side (top) after 21 days of recellularization from the side without 
perichondrium. Cells (black arrowheads) migrate through the matrix but stop where cartilage and 
CP meet. (e) H&E staining of full thickness (height >3mm, ∅ 8 mm) scaffolds injected with BMSCs 
and cultured six days culture in chondrogenic or expansion medium. Stars highlight injection sides, 
note that each scaffold was injected at three different points, but not all are visible in the sections 
shown. (f) Plot showing cells per mm2 in scaffolds with intact perichondrium injected with BMSCs 
after six days culture in chondrogenic or expansion medium. For each of three scaffolds twelve 
non-overlapping 0.1 mm2 fields were counted either on a section of the scaffold centre or a section 
800 μm further towards the outer perimeter. Error bars = SD. Blue bars indicate cell densities from 
literature for human nasal (n) [32], articular (range of all depths) (a) [33] as well as costal (c) 
cartilage [33]. (a)-(e) Scale bars = 200 µm. 
 
3.4 Restoration of glycosaminoglycans content and mechanical properties in a 
recellularized matrix that retains its size and shape 
Synthetic collagen-based scaffolds have been explored for cartilage tissue 
engineering but frequently shrink and distort due to cell contractions, especially during 
chondrogenic differentiation [34,35]. To estimate scaffold contraction, we compared 
the size of untreated auricular cartilage scaffolds to elastase-treated scaffolds 
recellularized with BMSCs or culture expanded ACs and then cultured in chondrogenic 
differentiation medium. As a reference for cell contraction, we seeded the same 
number of cells from the same donors onto an equally-sized collagen mesh 
(Matristypt™) used for tissue engineering [36]. The auricular cartilage scaffolds 
retained their shape and size after elastase treatment and during chondrogenic 
differentiation of BMSC or ACs, while the collagen mesh shrank severely (figure 4(a)). 
The height of elastase-treated and recellularized scaffolds (827 ± 102 µm) was similar 
to that of untreated scaffolds (735 ± 22 µm) (figure 4(b)). This indicates that elastase-
24 
 
treated auricular cartilage scaffolds resist distortion following reseeding and 
chondrogenic differentiation.   
The unique compressibility of articular cartilage is explained largely by 
glycosaminoglycans attracting fluid while trapped within a collagen network [20]. 
These glycosaminoglycans are however removed by elastase treatment 
(supplementary figure 1(a), (b)). We therefore investigated whether reseeded cells 
would restore the glycosaminoglycans of the matrix. After chondrogenic differentiation 
for 35 days, both BMSCs (figure 4(c)) and expanded ACs (figure 4(d), (e)) secreted 
glycosaminoglycans into the surrounding matrix. Thionin staining was localised to 
areas near cells, indicating that glycosaminoglycans are produced by the seeded cells 
and that their mobility is limited (figure 4(c)). We tested, using nanoindentation, 
whether local restoration of glycosaminoglycans would also restore mechanical 
properties. The stress-strain modulus increased from 27 kPa in unseeded matrix to 
between 39 kPa and 64 kPa, depending on the BMSC donor used, after 
recellularization and chondrogenic differentiation, and was significant (p<0.01) for 
BMSCs from 9 out of 10 donors (figure 4(f)). Mechanical properties and 
glycosaminoglycan secretion varied considerably between donors, with highly-
chondrogenic paediatric BMSCs [donor 1] showing the strongest thionin staining as 
well as the highest stress-strain modulus (figure 4(f), (g)). Although still significantly 
lower than the stress-strain modulus of 230 kPa for native bovine auricular cartilage 
(figure 4(f)), our findings suggest that restoration of glycosaminoglycans with 
recellularization promotes compression resistance of the elastase-treated auricular 
cartilage scaffolds, depending on the chondrogenic potential of the cells.  
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Figure 4. Elastase-treated auricular cartilage scaffolds retain size and shape and seeded cells 
restore glycosaminoglycans and mechanical properties. (a) H&E staining showing the full height of 
biopsies (∅6 mm) of bovine auricular cartilage (top row) and a collagen scaffold (Matristypt™) 
(bottom row) either untreated (first image) or seeded with 250,000 cells per sample (four different 
BMSC donors, one AC donor, matched in columns) and cultured for 35 days in chondrogenic 
medium. Scale bars = 200 µm. (b) Plot of mean height for three untreated bovine auricular cartilage 
and five recellularized, elastase-treated bovine auricular cartilage scaffolds after 30 days of culture. 
Per sample the shortest distance between the upper and lower sample sides was measured at 
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points 200 µm apart. Error bars = SD. (c) Stress-strain modulus determined by nanoindentation for 
untreated and elastase-treated bovine auricular cartilage as well as elastase-treated bovine 
auricular cartilage scaffolds recellularized with BMSCs from different donors and cultured in 
chondrogenic medium for 35 days. Values from a 16-point/sample indentation matrix for n=8 
(untreated), n=10 (elastase-treated) and per donor n>3 (recellularized) scaffolds. Two-tailed, 
asymptotic Kruskal-Wallis Test: pairwise comparison to elastase-treated scaffolds, adjusted 
significance: * p<0.01. (d) Thionin staining of scaffolds reseeded with BMSCs and chondrogenically 
differentiated for 35 days. Three representative scaffolds with windows highlighting superficial and 
central areas. Dotted lines indicate the border between scaffold and new matrix generated by 
seeded cells ex situ. Scale bars = 200 µm. (e), (f) Thionin staining of scaffolds with intact 
perichondrium injected with ACs and chondrogenically differentiated for 35 days. Dotted lines 
indicate the cartilage outer border, stars highlight injection sites. (e) Central area of a sample 
sectioned parallel to the perichondrium, (f) central area of different sample cut perpendicularly to 
the perichondrium. Scale bars = 200 µm. (g) Thionin staining for untreated and elastase-treated 
bovine auricular cartilage as well as representative elastase-treated bovine auricular cartilage 
scaffolds recellularized with adult and paediatric BMSCs from different donors and cultured in 
chondrogenic medium for 35 days (donor numbering as (c)). Scale bars = 200 µm. 
 
3.5 Chondrogenic cells invade elastase-treated auricular cartilage in vivo 
So far, we have shown that elastase-treated auricular cartilage scaffolds are rapidly 
recellularized in vitro. However, in some clinical applications, such as articular 
cartilage repair using matrix assisted chondrogenesis in combination with 
microfracture, in vivo recellularization is possible [37] and favourable requiring only 
one surgery and no in vitro culture. We therefore investigated if elastase-treated 
auricular cartilage scaffolds would be recellularized in vivo in an established articular 
cartilage defect model [16,17,38]. Osteochondral and chondral defects in bovine 
metacarpophalangeal joint biopsies were filled with cell-free elastase-treated bovine 
auricular cartilage scaffolds of thickness matching the defect size and then 
transplanted under the skin of immunocompromised mice. In chondral defects, cells 
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from the surrounding bovine articular cartilage entered the borders of the scaffold over 
ten weeks and formed cartilage de novo within (figure 5(a)) or adjacent to the scaffold 
(figure 5(b)). The amount of glycosaminoglycan synthesis however differed 
considerably between samples and none showed complete defect closure within this 
time frame. In osteochondral defects, cells invading from the bone marrow side 
distributed throughout the scaffold and formed new cartilage in situ within four weeks, 
connecting the scaffold to the surrounding cartilage (figure 5(c), (d)). After ten weeks, 
the cartilage tended to become hypertrophic (figure 5(e)) and in some areas was 
replaced by marrow-containing bone (figure 5(f)). Whereas this led to restoration of 
the subchondral defect area, the bone-like tissue extended throughout the defect up 
to the articular cartilage level, conceivably because this model lacks synovial fluid and 
mechanical loading. In osteochondral defects not filled with a scaffold, neither 
hypertrophic cartilage nor bone formed, instead the subchondral area was distorted, 
and the defect was filled by mostly sparse fibrous tissue (figure 5(g)). These findings 
indicate that in a joint defect model, elastase-treated bovine auricular cartilage 
scaffolds are rapidly invaded by chondrogenic cells.   
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Figure 5. Chondrogenic cells invade the elastase-treated auricular cartilage scaffold in vivo. (a)-(f) 
H&E and thionin staining of defects in osteochondral biopsies taken from bovine 
metacarpophalangeal joints, filled with elastase-treated auricular cartilage scaffolds and implanted 
subcutaneously into immunodeficient mice. (a), (b) Chondral defects after ten weeks and (c) 
osteochondral defects after two weeks, (d) four weeks and (e)/(f) ten weeks. (g) A control 
osteochondral defect left empty and harvested after ten weeks in vivo. Insets showing magnified area 
from a consecutive section stained for thionin shown for (a), (b), (e) and (f). Dotted lines indicate 
defect borders, scale bars = 200 µm. 
 
29 
 
 
Figure 6. Schematic Representation of Recellularization via Elastase-Generated Channels 
Elastase treatment of (xenogeneic) cartilage depletes elastin fibres as well as glycosaminoglycans 
from the matrix, resulting in a decrease in compression resistance, and facilitates removal of 
resident (xenogeneic) chondrocytes. Seeding of (autologous) chondrogenic cells then allows even 
recellularisation of the cartilage matrix via the channels left behind after elastin fibre removal. When 
induced to undergo chondrogenic differentiation, the invading cells rapidly generate new 
glycosaminoglycans within the matrix, partially restoring compression resistance.  
 
4. Discussion 
The dense matrix of cartilage is the principal hindrance to recellularization [13]. This 
study presents a method to make a cartilage-derived scaffold that is permeable to cells 
by the removal of elastin fibres from auricular cartilage (figure 6). We observed cells 
rapidly migrating along the channels left behind after elastin removal and distributing 
throughout the scaffold in vitro and in vivo. The invaded cells partially restored the 
glycosaminoglycans, with the scaffolds increasingly resembling cartilage in 
morphology and mechanics. While cartilage decellularization protocols permitting 
chondrogenesis of seeded cells have been reported previously, cell invasion was 
limited to less than 100 µm from the surface or perforations, presumably because 
migration occurred via lacunae that had been cut  open [8,39]. Our work significantly 
expands the applicability of cartilage recellularization approaches. The channels we 
create by removing elastin fibres extend through the entire auricular cartilage with the 
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exception of the perichondrium, allowing cells to rapidly recellularize the complete 
tissue. Articular and nasal septum cartilage defects less than 3 mm thick could be filled 
with a single layer of elastase-treated bovine auricular cartilage [40,41]. In order to 
imitate the zonal architecture of articular cartilage, it may be possible to retard cell 
migration unilaterally by taking advantage of the decrease of elastin fibre density 
towards the perichondrium. The complex shapes of ear and tracheal cartilage or 
thicker articular cartilage defects would likely require combining multiple scaffolds.  
While cartilage defects cause pain, they are, with the exception of those in the trachea, 
not life-threatening and thus rarely warrant the added risk inherent to immune 
suppression. We show that the scaffold can be derived from bovine or human auricular 
cartilage, with preliminary evidence indicating that the protocol is also applicable to 
porcine auricular cartilage [data not shown]. Elastase-treatment caused 
decellularization, which when combined with treatments to remove disease vectors 
and residual nucleic acids provides, in principle, non-immunogenic human allografts. 
Xenografts are not limited by donor material scarcity and the bovine auricle is 
considerably thicker and more plane than the human auricle, facilitating the design of 
larger scaffolds. While cellular bovine or porcine cartilage xenografts are immunogenic 
[42], xenogenic collagen matrices are routinely used for articular cartilage defect repair 
[43] and five decades of experience with porcine and bovine heart valves indicates 
that acellular xenografts have acceptable immunogenicity after reducing xenoantigens 
enzymatically [44]. Transplantation experiments in immunocompetent animals should 
be performed to confirm the low immunogenic nature of the decellularized scaffold 
before clinical application. 
Getting sufficient chondrogenic donor cells is a bottleneck for cartilage tissue 
engineering [45]. It is thus an asset that few cells efficiently recellularize large areas 
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and continue to proliferate within the scaffold. Extrapolating from ca. 8,500 cells we 
seeded per mm3 scaffold, a large 3 mm deep, 2.5 cm diameter (1470 mm3) articular 
cartilage defect would require 12 x 106 BMSCs, a number we routinely gain from 15 
ml bone marrow aspirates within ten days culture [22]. Similar numbers can be 
obtained for chondrocytes by expanding cells from a 1 mm diameter nasal septum 
biopsy [46] or directly from 7 g of articular cartilage [47].  Moreover, we show that 
elastase-treated auricular cartilage scaffold is directly suitable for defect shape-
matched cell-free implantation, permitting in vivo recellularization. Once treated with 
elastase the scaffold can be stored frozen and then cut to size and used off-the-shelf 
in clinical scenarios where chondrogenic cells are accessible in situ, e.g. 
microfracture-based articular cartilage repair [37].  
When placed in situ, cartilage scaffolds are exposed to considerable forces acting on 
the cartilage. When recellularized in vitro or in vivo, the elastase-treated auricular 
cartilage scaffolds showed only minor distortion while permitting in situ chondrogenic 
differentiation. This is a considerable benefit because balancing scaffold stiffness – 
high enough to prevent contraction, but not too high as to repress chondrogenic 
differentiation – is one of the most challenging aspects of cartilage scaffold design [48]. 
As expected, the chondrogenic potential of the seeded cells determined 
glycosaminoglycan restoration and thus compression resistance. We and others have 
shown that chondrogenic potential of cells varies greatly between donors, age groups 
and culture protocols [22,49–51]. In earlier studies, we found that WNT signalling 
agonists prevent the loss of chondrogenic potential during BMSCs expansion, and 
therefore we expanded all BMSCs with WNT3A [22,52]. Additional methods to improve 
glycosaminoglycan synthesis, e.g. sorting out the most potent cells, transient genetic 
manipulation, adjusting culture conditions or providing mechanical stimulation [53–58] 
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might further enhance restoration of glycosaminoglycan content. Combining these 
methods with elastase-treated auricular cartilage scaffolds may yield tissue 
engineered cartilage that approaches the properties of native cartilage. Whether the 
origin of the chondrogenic cells affects the properties of the generated cartilage, e.g. 
if nasal septum repair requires nasal chondrocytes, still needs to be explored. The 
tissue formed by ACs and BMSCs resembled hyaline cartilage, and we have shown 
earlier that neither auricular nor nasal chondrocytes express elastin in vitro [24]. 
However, auricular chondrocytes form structured elastin fibres in collagen scaffolds 
when transplanted in vivo [59].  
A prominent argument for decellularized scaffolds is that the matrix guides cell 
behaviour in a tissue-specific manner. While the effect on chondrogenic differentiation 
of aspects such as soluble matrix molecules, structural proteins, glycosaminoglycans, 
topography and mechanical force transmission have been studied [10,20,60–67], it 
remains unclear whether cartilage matrix itself stimulates chondrogenesis. Elastase 
treatment, while chemically mild compared to other decellularization procedures, 
depletes glycosaminoglycans, thereby likely removing soluble molecules, such as 
growth factors, bound to them. However, the complex type II collagen network appears 
to remain intact after elastin removal. Collagen matrices improve chondrogenesis by 
chondrocytes [68]. Moreover, type II collagen, which is unique to cartilage, has been 
suggested to increase chondrogenesis in BMSCs [69]. On a larger scale, fibres can 
guide cell migration and define cell shape [70]. Analysis of the collagen network in 
elastase-treated auricular cartilage may provide further insight into its role in 
chondroinduction.  
 
5. Conclusion 
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Elastase treatment of auricular cartilage provides a scaffold with channels that allow 
cell migration in the cartilage matrix and guide cells into a distribution resembling that 
of chondrocytes in native cartilage. When the invading cells, in vitro or in vivo, restore 
the glycosaminoglycans lost during elastase treatment, the resulting mixture of native 
and de novo generated matrix partly resembles that of intact articular cartilage. 
Moreover, the elastase-treated auricular cartilage appears resistant to deformation by 
cell contraction in vitro and in vivo, facilitating patient-tailored scaffold design. Our work 
addresses a major hurdle for cartilage-derived scaffolds: allowing recellularization 
while keeping the overall cartilage tissue architecture intact. Future research will need 
to show whether orthotopic zonal structures form upon implantation. 
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